EDGEMOND JAMES sold $5.4M of UTHR
EDGEMOND JAMES (CFO AND TREASURER) sold 10,000 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $540.15 ($533.59–$548.90, $5.40M total) across 14 trades on 2026-06-18 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the CFO/treasurer’s open-market sale totaling $5,401,488.51 across 14 trades on 2026-06-18, with a 10b5-1 plan noted.
Market read
Traders may monitor insider activity for sentiment, but this disclosure lacks any new fundamental catalyst and is mitigated by the pre-arranged 10b5-1 structure.
What to watch
The filing does not state tax/financing motives, and the remaining holdings (18,876 shares after) may reduce the signal strength versus a larger or non-10b5-1 sale.
Background
The article is a SEC Form 4 insider transaction disclosure for United Therapeutics (UTHR).
Ticker impact
United Therapeutics CFO and treasurer Edgemond James sold about $5.4M of UTHR shares via an open-market sale under a 10b5-1 plan.
Low likelihood of a sustained price move solely from this Form 4; any impact is likely short-lived and sentiment-driven.
The filing is a Form 4 insider transaction with a stated 10b5-1 pre-arranged plan; it discloses sale size, dates, and weighted-average price but no new company-specific operational or guidance information.
Market effects
Minimal read-through for biotech/pharma sector; this is company-specific insider activity without new regulatory/clinical catalysts.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.
Key entities
- issuerUNITED THERAPEUTICS Corp
Company whose shares were sold by an insider under a 10b5-1 plan.
- insiderEDGEMOND JAMES
CFO and treasurer who executed the open-market sale.
